Biocom Named Among “2026 China CRO Outstanding Brand Top 20” at 92nd PHARMCHINA

SHANGHAI – May 13, 2026 – Biocom, a leading full-chain pharmaceutical R&D service provider, has been honored as one of the “2026 China CRO Outstanding Brand Top 20” during the 92nd China Pharmaceutical Trade Fair (PHARMCHINA) held at the National Exhibition and Convention Center (Shanghai).

The prestigious list, widely recognized as a benchmark of excellence in China’s CRO industry, evaluates companies based on multiple dimensions including revenue and growth rate, net profit and growth rate, R&D investment, team size, brand influence, and leadership in specialized segments. Biocom stood out among its peers with its solid R&D capabilities and consistent business performance.

At the company’s exhibition booth, Biocom showcased its integrated, full-chain R&D service capabilities, drawing a steady stream of visitors and fostering in-depth discussions with upstream and downstream partners on end-to-end drug development collaboration.

“This recognition is a strong validation of Biocom’s comprehensive R&D strength and full-chain service capabilities,” said a company representative. “We are grateful to the industry and our partners for their continued trust and support.”

Over the years, Biocom has received multiple national and industry honors, including “National Technology Transfer Demonstration Institution,” “National High-tech Enterprise,” “2021 Industry Leader,” and “2025 China Top 20 CRO Enterprises.” Each milestone reinforces the company’s commitment to steady progress and professional excellence.

Looking forward, Biocom will continue to uphold its founding mission – “Innovating Quality Medicines for Public Health.” The company remains dedicated to advancing R&D, refining services, building long-term value for clients, and contributing to the high-quality development of China’s pharmaceutical industry in partnership with all stakeholders.

About Biocom
Biocom is a pharmaceutical R&D service provider offering full-chain drug development solutions. With a strong track record in technology transfer, high‑end R&D, and industry leadership, Biocom is committed to delivering innovative, high-quality medicines for public health.